---
title: "JPM Downgrades UBTECH ROBOTICS  to Neutral, Axes TP to HKD74"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300374829.md"
description: "JPMorgan downgraded UBTECH ROBOTICS to Neutral, cutting its Dec 2027 target price to HKD74 from HKD118, citing expectation resets and major pre-IPO investor share reductions. While maintaining a long-term growth outlook for humanoid robotics, JPM noted deployment complexities. The broker initiated coverage on YUSHU TECHNOLOGY with an Underweight rating due to competition and regulatory headwinds, while maintaining Overweight ratings on LEADER HARMONIOUS and ORBBEC, ranking them highest in preference."
datetime: "2026-09-29T03:20:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300374829.md)
  - [en](https://longbridge.com/en/news/300374829.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300374829.md)
generator: "portal-rs"
---

# JPM Downgrades UBTECH ROBOTICS  to Neutral, Axes TP to HKD74

JPMorgan released a research report downgrading UBTECH ROBOTICS (09880.HK) -1.900 (-2.578%) Short selling $98.79M; Ratio 26.451% from Overweight to Neutral, while slashing its TP for Dec 2027 to HKD74 from HKD118.

Embodied AI and humanoid robotics remain a multi-year growth story, but the transition toward mainstream deployment is proving more complex and selective than many expected, the broker said, forecasting global humanoid and legged robot shipments to rise from about 60,000 units in 2026 to about 1.75 million units in 2030, while China shipments are expected to expand from about 50,000 units to 900,000 units. 

JPMorgan downgraded UBTECH ROBOTICS owing to expectation resets and share reductions by major pre-IPO investors including TENCENT (00700.HK) -6.400 (-1.455%) Short selling $967.21M; Ratio 14.278% .

The broker also initiated coverage on YUSHU TECHNOLOGY (688836.SH) -7.470 (-1.625%) with an Underweight rating and a RMB300 TP, citing competition and regulatory scrutiny as near-term headwinds. In contrast, the broker maintained Overweight ratings on LEADER HARMONIOUS (688017.SH) -0.100 (-0.036%) and ORBBEC (688322.SH) -0.670 (-0.781%) , with latest Dec 2027 TPs of RMB358 and RMB110 respectively, believing their scarcity value, competitive moats and ecosystem positioning are the most defensive. 

The broker's preference ranking was: LEADER HARMONIOUS and ORBBEC tied for top place (both rated Overweight) > INOVANCE TECH (300124.SZ) +0.350 (+0.669%) (rated Neutral) > YIHEDA (301029.SZ) +0.020 (+0.082%) (rated Neutral) > UBTECH ROBOTICS > ESTUN (02715.HK) -0.120 (-0.850%) and YUSHU TECHNOLOGY tied for last place (both rated Underweight).  
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-09-28 16:25.) (A Shares quote is delayed for at least 15 mins.)

### Related Stocks

- [09880.HK](https://longbridge.com/en/quote/09880.HK.md)
- [688017.CN](https://longbridge.com/en/quote/688017.CN.md)
- [688322.CN](https://longbridge.com/en/quote/688322.CN.md)
- [688836.CN](https://longbridge.com/en/quote/688836.CN.md)
- [02715.HK](https://longbridge.com/en/quote/02715.HK.md)
- [00700.HK](https://longbridge.com/en/quote/00700.HK.md)
- [300124.CN](https://longbridge.com/en/quote/300124.CN.md)
- [301029.CN](https://longbridge.com/en/quote/301029.CN.md)

## Related News & Research

- [Chinese Robot Makers Boost Industrial Investment to Support Embodied AI Partners](https://longbridge.com/en/news/305435093.md)
- [MetaX and UBTech-backed robotics chip startup Xilect raises RMB 500 million](https://longbridge.com/en/news/305433026.md)
- [M Stanley: CN Humanoid Robot Stocks Spike but Commercialization Timeline Delayed; Scaling Expected to Follow Gradual Path](https://longbridge.com/en/news/305271213.md)
- [JOYSON ELEC  Delivers First High-Computing-Power Robot Brain Backpack to YUSHU TECHNOLOGY](https://longbridge.com/en/news/305400560.md)
- [UBTECH ROBOTICS  Partners With Tianyi Telecom Terminal to Promote Large-Scale Market Application of Biomimetic Humanoid Robots](https://longbridge.com/en/news/304975485.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**